tirzepatide surmount 1 SURMOUNT-1 Trial Tirzepatide for the treatment of

Let us guide you on your journey, ensuring each step is straightforward and supportive

Free consultation Benefits Triple mechanism of action only GLP-1 + GIP + glucagon agonist 40 mg in pen 4 full doses of 10 mg (up to 16 weeks with gradual escalation) 12 needles included + ALLUVI dosing instructions Isotonic solution, pH 6.57.5 comfortable injection Up to 24% weight loss over 48 weeks (Phase 2 study, NEJM 2023) Cold chain delivery with cooling elements (28C) across Ukraine Free 24/7 DOZA specialist support throughout the entire course Retatrutide 40 mg (ALLUVI) detailed description Retatrutide by ALLUVI Healthcare the world's first triple agonist targeting GLP-1, GIP and glucagon receptors in a convenient injection pen

10.1111/j.1600-0404.1990.tb00952.x 16

Consequently, several therapeutic approaches have aimed to antagonize GCG activity in the management of T2DM

In osteoarthritis, your body produces less hyaluronic acid, leading to increased friction and pain [1]